Evidence has demonstrated that S100A9 is elevated in various solid tumors and that the upregulation of S100A9 positively correlates with poor outcomes in colorectal, gastric, liver, pancreatic and prostate cancer [8–14]. This evidence concerns the gene S100A9 and prostate carcinoma.